Do you have $1,000 to invest in ASX 200 stocks?
If you do, then the stocks in this article could be great destinations for these funds according to analysts.
Here's what you need to know about them:
Endeavour Group Ltd (ASX: EDV)
This first ASX 200 stock that could be a buy according to analysts is Endeavour Group. It is the drinks giant that owns the BWS and Dan Murphy's brands, as well as a large network of hotels.
Goldmans Sachs is bullish on the company and feels its shares are undervalued at current levels. It recently said:
Net net, we reiterate Buy on our continued believe in a high quality retailer gaining share amid a category down-cycle with a resilient growth option in Hotels. Company is trading at FY25 P/E of 17x vs historical average of 22x and WOW 22x, COL 21x. Next catalyst: post Xmas trading at 1H25 results.
Goldman has a buy rating and $5.50 price target on its shares. This implies potential upside of 30% for investors from current levels.
In addition, an attractive fully franked 4.75% dividend yield is forecast for FY 2025.
Pilbara Minerals Ltd (ASX: PLS)
Another ASX 200 stock that could be a buy is lithium miner Pilbara Minerals.
That's the view of analysts at Bell Potter, which think that now could be the time to snap up its beaten down shares. Especially given its belief that the lithium market is heading into a supply deficit in 2026. It said:
We upgrade our PLS recommendation to Buy (from Hold) on recent share price weakness. […] We calculate that recent supply curtailments from Australian producers (including PLS) have removed around 50kt of Lithium Carbonate Equivalent from the market (around 4% of 2024 supply). On our supply-demand modelling, the cuts result in a smaller market surplus in 2025 and brings forward our estimate of a market deficit to 2026 (previously 2027).
Bell Potter has put a buy rating and $2.70 price target on its shares. This suggests that upside of 24% is possible over the next 12 months.
Pro Medicus Limited (ASX: PME)
Finally, Goldman Sachs also thinks that this high-flying health imaging technology company could be an ASX 200 share to buy.
While the broker acknowledges that Pro Medicus' shares are not cheap, it believes they deserve this premium valuation. Particularly given the company's significant long-term growth opportunity. The broker said:
We remain positive on the PME equity story as one of Australia's best global growth companies. […] PME is not cheap, trading on 114x FY26E EV/EBITDA, but we highlight its revenue/margin outlook, unique cloud offering, and significant long-term opportunity. Additionally, with a focus on the US regulatory outlook, we believe MedTech is increasingly being evaluated as a safe haven within healthcare as it is generally more insulated from impending policy volatility.
Goldman currently has a buy rating and $278.00 price target on its shares. This implies potential upside of 11% for investors between now and this time next year.
